Dana White Compared to Other Public TRT Figures

By
Published Updated Last reviewed
Hormone therapy clinical care image for Dana White Compared to Other Public TRT Figures

At a glance

  • Celebrity: Dana White, UFC president
  • Drug family: Testosterone replacement therapy (TRT)
  • Status: Publicly discussed; specific protocol details not confirmed
  • Public timeline: Body composition changes widely noted in 2023 and 2024
  • Comparison group: Joe Rogan, Robbie Williams, Dax Shepard, and other public TRT disclosures
  • Clinical relevance: TRT remains one of the most publicly discussed yet clinically misunderstood hormone therapies in men's health

Dana White's Public TRT Record

Dana White's health transformation became a widely covered story in late 2023 after he appeared noticeably leaner and more muscular across UFC broadcast appearances and social media posts. White has spoken openly about a health scare that prompted major lifestyle changes, including consultations with physicians focused on longevity medicine. In a September 2023 appearance on the Flagrant podcast, White discussed working with a doctor who put him on a comprehensive protocol that included testosterone optimization, though he did not disclose specific compounds, dosages, or lab work.

It is important to note: White confirmed TRT in broad strokes. He has not disclosed whether he uses injectable testosterone cypionate, topical gels, or other formulations. He has not shared baseline or follow-up testosterone levels publicly. The specifics of his protocol remain speculated by fans and commentators, not confirmed by White or his medical team.

This matters because TRT is not a single intervention. The Endocrine Society's 2018 clinical practice guidelines define testosterone deficiency as total testosterone below 300 ng/dL on at least two morning measurements, combined with symptoms. Treatment protocols vary significantly based on the formulation chosen, with injectable testosterone cypionate typically dosed at 100 to 200 mg every one to two weeks, while topical gels deliver 50 to 100 mg daily with different pharmacokinetic profiles.

The Growing List of Public TRT Disclosures

White is far from alone. Several male public figures have discussed TRT with varying degrees of specificity, forming an informal public record that the HealthRX Medical Team has tracked across the celebrity series.

Joe Rogan represents the most detailed public disclosure. Rogan has discussed TRT extensively on his podcast over many years, confirming injectable testosterone use, sharing that he monitors bloodwork regularly, and discussing ancillary medications like anastrozole for estrogen management. Rogan has also been transparent about combining TRT with growth hormone, placing his disclosure in a category of unusual openness. His willingness to discuss dose adjustments and side effects (including elevated hematocrit) provides a rare public window into monitored TRT.

Robbie Williams confirmed TRT use in a 2023 interview with The Times, framing it as part of managing energy levels and mood in his late 40s. Williams offered less clinical detail than Rogan but was unambiguous about the therapy itself.

Dax Shepard discussed testosterone therapy on his Armchair Expert podcast, confirming he used it and describing effects on energy and body composition. Shepard's disclosure was notable for its candor about the psychological appeal of the therapy, not just the physical outcomes.

Other figures in the broader public conversation include Vince McMahon (speculated, associated with WWE's historical entanglement with performance-enhancing drugs but never personally confirmed as therapeutic TRT), and various fitness influencers who blur the line between therapeutic replacement and supraphysiological dosing. The distinction is clinically critical: therapeutic TRT targets levels of 450 to 700 ng/dL, while bodybuilding-adjacent protocols often push total testosterone above 1 to 500 ng/dL, a range associated with substantially different risk profiles per cardiovascular outcome data published in the New England Journal of Medicine.

Disclosure Patterns: What the Public Record Shows

The HealthRX Medical Team identifies three distinct disclosure patterns among public TRT figures:

Pattern 1: Full clinical transparency. Joe Rogan fits here. Bloodwork discussed publicly, formulations named, side effects acknowledged, ancillary medications disclosed. This pattern gives audiences the most accurate picture of what monitored TRT actually involves.

Pattern 2: Confirmed use, limited detail. Dana White, Robbie Williams, and Dax Shepard fall into this group. They confirm the therapy exists in their regimen but do not share dosing, labs, or formulation specifics. This is the most common pattern, and while it reduces stigma around the therapy, it leaves significant gaps. Audiences know the celebrity uses TRT but cannot assess whether the protocol is conservative replacement or aggressive optimization.

Pattern 3: Speculated only. Figures whose physical changes prompt public speculation but who have not confirmed TRT use. The HealthRX Medical Team does not attribute TRT use to anyone in this category. Body composition changes can result from training, diet, other medications (including GLP-1 agonists, which White has also been linked to), or combinations of interventions.

A 2020 review in the Journal of Clinical Endocrinology & Metabolism found that testosterone prescriptions in the United States increased roughly threefold between 2001 and 2013, driven partly by direct-to-consumer advertising and cultural normalization. Celebrity disclosures, even incomplete ones, contribute to that normalization effect.

Clinical Context: What TRT Actually Does (and Doesn't Do)

For readers encountering TRT through celebrity stories, the HealthRX Medical Team emphasizes several clinical realities that public disclosures often skip.

Diagnosis comes first. The American Urological Association recommends confirming low testosterone with at least two morning serum measurements before initiating therapy. Symptoms alone (fatigue, low libido, reduced muscle mass) are nonspecific and overlap with depression, sleep disorders, thyroid dysfunction, and dozens of other conditions.

Cardiovascular risk is real but nuanced. The TRAVERSE trial, published in NEJM in 2023, followed over 5,000 men aged 45 to 80 with hypogonadism and established cardiovascular disease or high cardiovascular risk. Results showed that transdermal testosterone did not significantly increase the incidence of major adverse cardiac events compared to placebo over a mean follow-up of 33 months. This was reassuring but not a blanket safety clearance. The study population was carefully selected, and the formulation was topical gel, not injectable testosterone at higher doses.

Hematocrit monitoring is non-negotiable. Testosterone stimulates erythropoiesis. Hematocrit levels above 54% increase the risk of thromboembolic events. The Endocrine Society guidelines recommend checking hematocrit at baseline, at three to six months, and then annually. Joe Rogan has mentioned this monitoring publicly. Most other celebrity disclosures do not address it.

Fertility suppression is a major consideration. Exogenous testosterone suppresses gonadotropins (LH, FSH), which reduces or eliminates spermatogenesis in most men. This is reversible in many cases after discontinuation, but recovery can take 6 to 18 months, and some men do not fully recover. For men of reproductive age, alternatives like clomiphene citrate or enclomiphene can raise endogenous testosterone without suppressing sperm production. None of the public figures discussed here have addressed fertility implications in their disclosures.

Prostate safety requires ongoing surveillance. While TRT does not appear to cause prostate cancer in men without pre-existing disease, the FDA label still requires periodic PSA and digital rectal exam monitoring. Men with untreated prostate cancer remain contraindicated for TRT.

Why Dana White's Position Carries Outsized Influence

White is not just a celebrity. As UFC president, he oversees a sport with a complicated TRT history. The UFC allowed therapeutic use exemptions (TUEs) for testosterone until 2014, when USADA partnership effectively ended that practice. Fighters like Vitor Belfort, Chael Sonnen, and Dan Henderson used TRT under TUE provisions, and the policy reversal remains one of the most debated regulatory decisions in combat sports history.

When White discusses his own TRT use publicly, it carries a different weight than an actor or musician doing the same. His audience includes active fighters, coaches, and athletic commissions. The HealthRX Medical Team notes that this creates a responsibility gap: White's broad confirmation without clinical detail may signal to his audience that TRT is straightforward, when in practice it requires careful diagnostic workup, ongoing monitoring, and individualized dosing.

This is not a criticism of White's personal health choices. It is an observation that platform size and audience composition affect the clinical stakes of incomplete disclosure.

The HealthRX Medical Team Take

The pattern across public TRT disclosures is consistent: confirmation without clinical specificity. Dana White, like most public figures, has acknowledged TRT as part of his regimen without providing the details that would allow clinical evaluation of that choice. This is his right. But it leaves a gap between what audiences hear ("TRT works") and what the clinical evidence shows ("TRT works for specific patients, with specific diagnostic criteria, under specific monitoring protocols, with specific risks").

The most useful public TRT disclosure would include: a confirmed diagnosis of hypogonadism, the formulation and dose used, baseline and follow-up lab values (total testosterone, free testosterone, hematocrit, PSA, estradiol), and an honest account of side effects. No public figure has provided all of these elements, though Rogan comes closest.

For men considering TRT based on what they see in public figures, the HealthRX Medical Team recommends: get two morning testosterone draws before any conversation about treatment. Confirm the diagnosis before choosing the therapy. And understand that what works for a 55-year-old CEO with access to concierge medicine may not map onto your clinical situation without modification.

Frequently asked questions

›
›
›
›
›

References